Biohaven Posts Positive Migraine Results, But Investors Are Wary
Executive Summary
Biohaven's stock price fell significantly after it reported positive Phase III results for rimegepant in the acute treatment of migraine, but concerns about differences between the company's Phase II and III data eased as potential benefits over Allergan's competing oral CGRP inhibitor emerged.
You may also be interested in...
Biohaven's Oral Rimegepant Poised To Alter Migraine Market
Clinical data on the US biotech’s oral CGRP antagonist underlines its potential to change the dynamics of the migraine sector.
Keeping Track: US Approvals For Xpovio And Xembify Highlight Short Holiday Week
The latest drug development news and highlights from our US FDA Performance Tracker.
J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven And Lilly
Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: Biogen may be looking for gene therapy partner, Lilly CEO says Loxo is just the start, GSK plays up its BCMA, Amgen vows to put money into deals, Biohaven readies oral CGRP inhibitor to compete, and Roche talks value-based payments.